Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Skin And Oral Lesions Associated To Imatinib Mesylate Therapy.
Author: Basso, Fernanda Gonçalves
Boer, Camila Cominato
Corrêa, Maria Elvira Pizzigatti
Torrezan, Marcia
Cintra, Maria Letícia
de Magalhães, Marina H C Gallottini
da Silva Santos, Paulo
de Souza, Cármino Antônio
Abstract: Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.
Subject: Aged, 80 And Over
Antineoplastic Agents
Dose-response Relationship, Drug
Drug Eruptions
Leukemia, Myelogenous, Chronic, Bcr-abl Positive
Middle Aged
Oral Ulcer
Protein Kinase Inhibitors
Citation: Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer. v. 17, n. 4, p. 465-8, 2009-Apr.
Rights: fechado
Identifier DOI: 10.1007/s00520-008-0536-8
Date Issue: 2009
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_19037666.pdf228.18 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.